Develops and delivers Duplex Sequencing technology for highly accurate detection of ultra-low-frequency genomic variants
Develops and delivers Duplex Sequencing technology for highly accurate detection of ultra-low-frequency genomic variants. Its applications include minimal/measurable residual disease (MRD) and circulating tumor DNA detection in cancer research, genetic toxicology, clinical medicine, public health, and life sciences. The company develops products and collaborates with pharmaceutical companies, academic centers, clinical research networks, and regulatory agencies.